


# Dose-escalated radn does not up survival in localized prostate CA

March 16 2018

---



(HealthDay)—Dose escalation from 70.2 to 79.2 Gy is not associated

with improved overall survival (OS) in intermediate-risk prostate cancer, according to a study published online March 15 in *JAMA Oncology*.

Jeff M. Michalski, M.D., from Washington University in St. Louis, and colleagues randomized 1,532 men with stage cT1b to T2b, Gleason score 2 to 6, and [prostate-specific antigen](#) (PSA) level of  $\geq 10$  and

Citation: Dose-escalated radn does not up survival in localized prostate CA (2018, March 16)  
retrieved 25 April 2024 from

<https://medicalxpress.com/news/2018-03-dose-escalated-radn-survival-localized-prostate.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.